News blog

York Pharma

  • BY: Andrew Hore |
  • POSTED: 28/10/2008 |

Skin treatments developer York Pharma has bought the rights to new products from the administrator of Celltran.

York is buying the assets for £70,000 plus royalties on sales over a five year period. It has also raised £510,000 at 14.4p a share.

Myskin and Cryoskin are two products are already being marketed or the treatment of chronic wounds and burns. There is also a pipeline of other potential products.

Sheffield-based Celltran has invested £5m in developing its products and acquired another product in which £10m had been invested. Myskin and Cryoskin fit well with Flammazine and Flammacerium, which were recently acquired by York. The same sales team can sell all the products so there won’t be any extra costs.

Other potential products acquired include Lyphoderm, which has completed a phase II trial on venous leg ulcer patients, Ulcodress, a hydrogel wound dressing, Myskin Vitiligo, for the treatment of an intractable skin depigmentation, and Myskin Cornea, for the treatment of corneal damage.

At 18p a share, York is valued at £10.3m.

Results for the year to September 2008 will be reported on 23 January. 

© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds